A pilot study on prostate cancer risk and pro-inflammatory genotypes: Pathophysiology and therapeutic implications

Current Pharmaceutical Design

Volumn 16, Issue 6, 2010, Pages 718-724

  Balistreri, C R ^a   Caruso, C ^a   Carruba, G ^a,b   Miceli, V ^a,b   Campisi, I ^b   Listi F ^a   Lio, D ^a   Colonna Romano, G ^a   Candore, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Dipartimento di Neuroscienze   (Italy)

Author keywords

5 LO; Genetics; Inflammation; Prostate cancer (PC); PTGS2; SNP; TLR2; TLR4

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 2; PROSTAGLANDIN E SYNTHASE; PROTEIN PTGS 2; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; AUTACOID;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; GENE CLUSTER; GENE FREQUENCY; GENOTYPE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; COMPARATIVE STUDY; GENETICS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PILOT STUDY; PROSTATIC NEOPLASMS; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; GENOTYPE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 77950230515     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790883877     Document Type: Article

References (30)

1. Lin BK, Clyne M, Walsh M, Gomez O, Yu W, Gwinn M, et al. Tracking the epidemiology of human genes in the literature: the HuGE Published Literature database. Am J Epidemiol 2006; 164: 1-4.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
3. Maroni PD, Crawford ED. Screening for prostate cancer in 2006: PSA in the 21st century. N C Med J 2006; 67: 136-139
4. Barry MJ. Screening for prostate cancer - the controversy that refuses to die. N Engl J Med 2009; 360: 1351-1354
5. Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 2008; 54: 1951-1960
6. Caruso C, Balistreri CR, Candore G, Carruba G, Colonna-Romano G, Di BonA D, et al. Polymorphisms of pro-inflammatory genes and Prostate Cancer risk: a pharmacogenomic approach, Cancer Immunol Immunother 2009; 58(12): 1919-1933
7. Bensalah K, Lotan Y, Karam JA, Shariat SF. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis 2008; 11: 112-120
8. Shariat SF, Karam JA, Margulis V, Karakiewicz PI. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Int 2008; 101: 675-683
9. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004; 13: R103-21.
10. Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 2008; 299: 2423-2436
11. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008; 359: 2143-2153
12. Cevenini E, Invidia L, Lescai F, Salvioli S, Tieri P, Castellani G, et al. Human models of aging and longevity. Expert Opin Biol Ther 2008; 8: 1393-1405
13. Vasto S, Carruba G, Lio D, Colonna-Romano G, Di Bona D, Candore G, et al. Inflammation, ageing and cancer. Mech Ageing Dev 2009; 130: 40-45
14. Imyanitov EN. Use of elderly tumor-free subjects as a "supercontrol" for cancer epidemiological studies: pros and cons. Mech Ageing Dev 2009; 130: 122-127
15. Balistreri CR, Candore G, Lio D, Colonna-Romano G, Di Lorenzo G, Mansueto P, et al. Role of TLR4 receptor polymorphisms in Boutonneuse fever. Int J Immunopathol Pharmacol 2005; 18: 655-660
16. Balistreri CR, Candore G, Mirabile M, Lio D, Caimi G, Incalcaterra E, et al. TLR2 and age-related diseases: potential effects of Arg753Gln and Arg677Trp polymorphisms in acute myocardial infarction. Rejuvenation Res 2008; 11: 293-296
17. Listì F, Caruso M, Incalcaterra E, Hoffmann E, Caimi G, Balistreri CR, et al. Pro-inflammatory gene variants in myocardial infarction and longevity: implications for pharmacogenomics. Curr Pharm Des 2008; 14: 2678-2685
18. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-269
19. Hold GL, El-Omar ME. Genetic aspects of inflammation and cancer. Biochem J 2008; 410: 225-235
20. Sutcliffe S, Platz EA. Inflammation and prostate cancer: a focus on infections. Curr Urol Rep 2008; 9: 243-249
21. Nelson WG, DeWeese TL, De Marzo AM. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002; 21: 3-16.
22. Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem 2007; 102: 899-911.
23. Voisey J, Morris CP. SNP technologies for drug discovery: a current review. Curr Drug Discov Technol 2008; 5: 230-235
24. Chen Y, Zhu J, Lum PY, Yang X, Pinto S, MacNeil DJ, et al. Variations in DNA elucidate molecular networks that cause disease. Nature 2008; 452: 429-435
25. Candore G, Balistreri CR, Caruso M, Grimaldi MP, Incalcaterra E, Listì F, et al. Pharmacogenomics: a tool to prevent and cure coronary heart disease. Curr Pharm Des 2007; 13: 3726-3734
26. Candore G, Balistreri CR, Grimaldi MP, Listì F, Vasto S, Chiappelli M, et al. Polymorphisms of pro-inflammatory genes and Alzheimer's disease risk: a pharmacogenomic approach. Mech Ageing Dev 2007; 128: 67-75.
27. Wang RF, Miyahara Y, Wang HY. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 2008; 27: 181-189
28. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol 2008; 8: 327-336
29. Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 2008; 100: 35-83.
30. Perneger TV. What's wrong with Bonferroni adjustments? Br Med J 1998; 316: 1236-1238